Levomilnacipran Hydrochloride Patent Expiration
Levomilnacipran Hydrochloride is used for treating Major Depressive Disorder (MDD) It was first introduced by Abbvie Inc
Levomilnacipran Hydrochloride Patents
Given below is the list of patents protecting Levomilnacipran Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fetzima | US8481598 | Stable dosage forms of levomilnacipran | Mar 02, 2031 | Abbvie |
| Fetzima | US8865937 | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide | May 23, 2032 | Abbvie |
| Fetzima | USRE43879 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | Jan 11, 2026 | Abbvie |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Levomilnacipran Hydrochloride Generics
Several generic applications have been filed for Levomilnacipran Hydrochloride. The first generic version for Levomilnacipran Hydrochloride was by Amneal Pharmaceuticals Co Gmbh and was approved on Feb 4, 2019. And the latest generic version is by Prinston Pharmaceutical Inc and was approved on Mar 20, 2023.
Given below is the list of companies who have filed for Levomilnacipran Hydrochloride generic.
1. PRINSTON INC
Prinston Pharmaceutical Inc has filed for 4 different strengths of generic version for Levomilnacipran Hydrochloride. Given below are the details of the strengths of this generic introduced by Prinston Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE | capsule, extended release | Prescription | ORAL | AB | Mar 20, 2023 |
| EQ 120MG BASE | capsule, extended release | Prescription | ORAL | AB | Mar 20, 2023 |
| EQ 80MG BASE | capsule, extended release | Prescription | ORAL | AB | Mar 20, 2023 |
| EQ 40MG BASE | capsule, extended release | Prescription | ORAL | AB | Mar 20, 2023 |
2. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 4 different strengths of generic version for Levomilnacipran Hydrochloride. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 120MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Jan 6, 2023 |
| EQ 20MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Jan 6, 2023 |
| EQ 40MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Jan 6, 2023 |
| EQ 80MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Jan 6, 2023 |
3. AMNEAL PHARMS CO
Amneal Pharmaceuticals Co Gmbh has filed for 4 different strengths of generic version for Levomilnacipran Hydrochloride. Given below are the details of the strengths of this generic introduced by Amneal Pharms Co.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Feb 4, 2019 |
| EQ 120MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Feb 4, 2019 |
| EQ 80MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Feb 4, 2019 |
| EQ 40MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Feb 4, 2019 |
4. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Levomilnacipran Hydrochloride. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Nov 5, 2020 |
| EQ 40MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Nov 5, 2020 |
| EQ 80MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Nov 5, 2020 |
| EQ 120MG BASE | capsule, extended release | Discontinued | ORAL | N/A | Nov 5, 2020 |